Medlab Clinical Ltd (ASX: MDC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medlab Clinical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.07 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.28 million
Earnings per share -1.714
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medlab Clinical Ltd (ASX: MDC)
    Latest News

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Healthcare Shares

    Why is the Medlab (ASX:MDC) share price surging 8% today?

    The Medlab (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant Nanocelle…

    Read more »

    high share price
    Share Market News

    Here's why the Medlab (ASX:MDC) share price is rising today

    The Medlab Clinical Ltd (ASX: MDC) share price is treading upwards today after announcing an agreement Arrotex. Here's what you…

    Read more »

    a woman
    Share Gainers

    Why Clean TeQ, Medlab, Newcrest, & Ramelius are storming higher today

    Medlab Clinical Ltd (ASX:MDC) and Newcrest Mining Limited (ASX:NCM) shares are storming higher on Monday. Here's why...

    Read more »

    a woman
    Share Gainers

    Why this ASX cannabis share is shooting 15% higher today

    The Medlab Clinical Ltd (ASX:MDC) share price is shooting higher on Monday despite the market selloff. Here's why this cannabis…

    Read more »

    a woman
    Share Gainers

    Why THC Global and these ASX cannabis shares are rocketing higher today

    The THC Global Group Ltd (ASX:THC) share price and these cannabis shares are rocketing higher on Monday. Here's why...

    Read more »

    a woman
    52-Week Highs

    Why this ASX biotech is printing 52-week highs

    The Medlab Clinical Ltd (ASX: MDC) share price is rising after the company announced it has signed a Heads of Agreement…

    Read more »

    a woman
    Share Gainers

    This small-cap ASX biotech's share price is soaring today

    An operations update for the June quarter sees the Medlab Clinical Ltd (ASX: MDC) share price soar in Thursday trade.

    Read more »

    a woman
    Share Gainers

    Why Medlab, Metcash, SKY and Space Global, and WiseTech shares charged higher today

    The Metcash Limited (ASX:MTS) share price and the WiseTech Global Ltd (ASX:WTC) share price are two of four charging higher…

    Read more »

    a woman
    Share Market News

    These small cap ASX shares are on the rise today

    The Slater & Gordon Limited (ASX:SGH) share price is one of three in the small cap space climbing higher on…

    Read more »

    a woman
    ⏸️ Investing

    Is Medlab Clinical Ltd the best small cap healthcare buy on the ASX?

    brokers are circling biological research company Medlab Clinical Ltd (ASX: MDC) as a potential buy

    Read more »

    a woman
    ⏸️ Investing

    Why these pot stocks are moving higher

    Pot stocks continue to provide investors with strong returns…

    Read more »

    a woman
    ⏸️ Investing

    Why shares of Medlab Clinical Ltd have risen 37% in 2018

    Shares of Medlab Clinical Ltd (ASX:MDC) have had an excellent start to 2018 with the company's share price rising 37% to…

    Read more »

    MDC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medlab Clinical Ltd

    Medlab Clinical Ltd is an Australian biotechnology company that specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals to empower patients with chronic diseases and mental health conditions and enhance their lives.. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B, and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Matthew John Hudson Non-Executive Director Mar 2023
    Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy, which operates 43 oil and gas wells across Kansas and Oklahoma. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
    Mr Sean Michael Hall Chief Executive Officer Apr 2014
    Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
    Mr Tim Walker Non-Executive Director Mar 2024
    Mr Walker has experience in originating, managing, and leading a variety resource transaction. Specifically, in M&A transactions across the Canadian and Australian markets, IPOs, and both equity and debt financing solutions. Tims past directorships with exploration companies have provided him a experience across various commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
    Mr Edmond Tan Non-Executive Director Mar 2024
    Mr Tan has 10 years experience in various roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a specific focus on foreign investment into Australia. Currently, Edmond is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
    Mr Kerem Kaya Chief Financial OfficerCompany Secretary May 2021
    -
    Kerem Kaya Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No top 20 shareholder's information disclosed 0 0.00%

    Profile

    since

    Note